Protocol Review and Monitoring System (PRMS) The conduct of cancer clinical trials is central to the scientific mission of the University of Arizona Cancer Center (UACC). The development and implementation of a broad portfolio of cancer trials requires an extensive institutional commitment of scientific, operational, and patient resources; thus, oversight of the scientific merit and progress of the trial portfolio is paramount in ensuring that trial outcomes help shape the future of cancer prevention and treatment. The internal oversight of the scientific aspects of all cancer trials and the monitoring of the progress of cancer trials research is managed by the UACC Protocol Review and Monitoring System (PRMS). The Scientific Review Committee (SRC) serves as the principal functional component of the PRMS; it is the chartered, multidisciplinary body charged with the ultimate review of the scientific merit, prioritization, and progress of all cancer trials proposed by UACC Principal Investigators, with the exception of those trials that have undergone external peer-review through NIH and its funding agencies. The SRC membership is composed of a broad spectrum of specialists in cancer treatment, cancer prevention, therapeutic development, and basic and population science that mirrors the breadth of the UACC's clinical trial portfolio. Cancer trials are risk-stratified for determination of need for full Committee versus administrative expedited review. A systematic process is in place for the monitoring of accrual to trials and of trial scientific progress. The SRC has the authority to terminate trials that have not met pre-specified accrual targets or that are not meeting their scientific objectives. The PRMS performance metrics are generated by the clinical research system OnCore and provide the basis for PRMS quality improvement initiatives.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA023074-39
Application #
9735142
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
39
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Lent, Adrienne B; O'Connor, Patrick A; Reikowsky, Ryan C et al. (2018) Quit outcomes among clients ineligible for cessation medication through the state quitline: a retrospective, observational study. BMC Public Health 18:1001
Bea, J W; Hsu, C-H; Blew, R M et al. (2018) Use of iDXA spine scans to evaluate total and visceral abdominal fat. Am J Hum Biol 30:
Bulkley, Joanna E; McMullen, Carmit K; Grant, Marcia et al. (2018) Ongoing ostomy self-care challenges of long-term rectal cancer survivors. Support Care Cancer 26:3933-3939
Zaim, Samir Rachid; Li, Qike; Schissler, A Grant et al. (2018) Emergence of pathway-level composite biomarkers from converging gene set signals of heterogeneous transcriptomic responses. Pac Symp Biocomput 23:484-495
Kobes, Joseph E; Georgiev, George I; Louis, Anthony V et al. (2018) A Comparison of Iron Oxide Particles and Silica Particles for Tracking Organ Recellularization. Mol Imaging 17:1536012118787322
Kelly, K R; Espitia, C M; Zhao, W et al. (2018) Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia 32:230-233
Downs, Charles A; Johnson, Nicholle M; Tsaprailis, George et al. (2018) RAGE-induced changes in the proteome of alveolar epithelial cells. J Proteomics 177:11-20
Sun, Virginia; Wendel, Christopher S; Demark-Wahnefried, Wendy et al. (2018) Diet and Behavior Modifications by Long-term Rectal Cancer Survivors to Manage Bowel Dysfunction-Associated Symptoms. Nutr Cancer :1-11
Mushtaq, Adeela; Kapoor, Vikas; Latif, Azka et al. (2018) Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review. Crit Rev Oncol Hematol 125:1-11
Rak, Michael A; Buehler, Jason; Zeltzer, Sebastian et al. (2018) Human Cytomegalovirus UL135 Interacts with Host Adaptor Proteins To Regulate Epidermal Growth Factor Receptor and Reactivation from Latency. J Virol 92:

Showing the most recent 10 out of 1336 publications